POU5F1 and metabolic dysfunction-associated steatohepatitis: These findings indicated that, comparing with senescent primary hepatocytes from aged donors, an Oct4/Sox2/Klf4/Parp1-reprogrammed iPSCs from senescent cells may be a better cell source for the treatment of NASH (Figure 7).